These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35362158)

  • 1. Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems.
    Leung HH; Puspanathan P; Chan AW; Nik Mustapha NR; Wong VW; Chan WK
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1131-1138. PubMed ID: 35362158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease.
    Juluri R; Vuppalanchi R; Olson J; Unalp A; Van Natta ML; Cummings OW; Tonascia J; Chalasani N
    J Clin Gastroenterol; 2011 Jan; 45(1):55-8. PubMed ID: 20505526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
    Kleiner DE; Brunt EM; Van Natta M; Behling C; Contos MJ; Cummings OW; Ferrell LD; Liu YC; Torbenson MS; Unalp-Arida A; Yeh M; McCullough AJ; Sanyal AJ;
    Hepatology; 2005 Jun; 41(6):1313-21. PubMed ID: 15915461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
    Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
    J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
    Giashuddin S; Alawad M
    Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Liu F; Goh GB; Tiniakos D; Wee A; Leow WQ; Zhao JM; Rao HY; Wang XX; Wang Q; Wan WK; Lim KH; Romero-Gomez M; Petta S; Bugianesi E; Tan CK; Harrison SA; Anstee QM; Chang PJ; Wei L
    Hepatology; 2020 Jun; 71(6):1953-1966. PubMed ID: 31600834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
    Sergi CM
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
    Brunt EM; Clouston AD; Goodman Z; Guy C; Kleiner DE; Lackner C; Tiniakos DG; Wee A; Yeh M; Leow WQ; Chng E; Ren Y; Boon Bee GG; Powell EE; Rinella M; Sanyal AJ; Neuschwander-Tetri B; Younossi Z; Charlton M; Ratziu V; Harrison SA; Tai D; Anstee QM
    J Hepatol; 2022 May; 76(5):1030-1041. PubMed ID: 35090960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research progress on the histological scoring system for nonalcoholic fatty liver disease].
    Li J; Ge QY; Song QY; Zhang ZH
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):765-769. PubMed ID: 37580263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology.
    Liang W; Menke AL; Driessen A; Koek GH; Lindeman JH; Stoop R; Havekes LM; Kleemann R; van den Hoek AM
    PLoS One; 2014; 9(12):e115922. PubMed ID: 25535951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A scoring system for the diagnosis of non-alcoholic steatohepatitis from liver biopsy.
    Lee K; Jung ES; Yu E; Kang YK; Cho MY; Kim JM; Moon WS; Jeong JS; Park CK; Park JB; Kang DY; Sohn JH; Jin SY
    J Pathol Transl Med; 2020 May; 54(3):228-236. PubMed ID: 32460476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathology, grading and staging of nonalcoholic fatty liver disease.
    Kleiner DE
    Minerva Gastroenterol Dietol; 2018 Mar; 64(1):28-38. PubMed ID: 28948754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study.
    Sanyal AJ; Loomba R; Anstee QM; Ratziu V; Kowdley KV; Rinella ME; Harrison SA; Resnick MB; Capozza T; Sawhney S; Shelat N; Younossi ZM
    Hepatol Commun; 2024 Jan; 8(1):. PubMed ID: 38126958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
    Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
    J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology of non-alcoholic fatty liver disease.
    Bedossa P
    Liver Int; 2017 Jan; 37 Suppl 1():85-89. PubMed ID: 28052629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
    Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.